CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 776 enrolled
Drug / intervention
azelastine HCl/fluticasone propionate +3 moredrug
Likely dose
azelastine HCl/fluticasone propionate 548 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00740792
NCT00740792Phase 3Completed
CompareCT.gov

Randomized, Double-Blind Trial of MP29-02 Nasal Spray Compared to Placebo, Azelastine Hydrochloride Nasal Spray, and Fluticasone Propionate Nasal Spray in the Treatment of Patients With Seasonal Allergic Rhinitis.

Meda Pharmaceuticals·interventional·Posted Aug 25, 2008·Updated Sep 7, 2012

In Brief

A Phase 3 clinical trial evaluating azelastine HCl/fluticasone propionate, azelastine Hcl, and 2 other interventions for Seasonal Allergic Rhinitis. Completed, enrolled 776 participants across 39 sites.

Detailed Summary

The purpose of this study is to determine if two allergy medications (formulated azelastine and fluticasone product) are more effective than placebo or either medication alone (azelastine or fluticasone)

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSeasonal Allergic Rhinitis
CountriesUnited States
Collaborators--

Timeline

Phase 3CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 25, 2008
Enrollment StartAug 1, 2008
Primary CompletionNov 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 17.9 years ago

Interventions

azelastine HCl/fluticasone propionatedrug

azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID

azelastine Hcldrug

azelastine Hcl 548 mcg one spray per nostril BID

fluticasone propionatedrug

fluticasone propionate 200 mcg one spray per nostril BID

placebodrug

placebo one spray per nostril BID